Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks

被引:46
作者
Mars, LT
Novak, J
Liblau, RS [1 ]
Lehuen, A
机构
[1] Hop Purpan, INSERM U563, Toulouse, France
[2] Hop St Vincent de Paul, INSERM U561, F-75674 Paris, France
[3] Ctr Hosp Univ Toulouse, Immunol Lab, Toulouse, France
关键词
D O I
10.1016/j.it.2004.07.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Invariant NKT (iNKT) cells are a unique T cell subset that upon activation promptly produce copious amounts of pro- and anti-inflammatory cytokines, thereby contributing to both innate and acquired immunity. Animal models of autoimmune diseases suggest that iNKT cells favor immune regulation because their absence enhances autoimmunity in some models, whereas their enrichment alleviates autoimmune manifestations. Moreover, convergent experiments indicate that therapeutic targeting of iNKT cells can potentiate their immunoregulatory properties. Therefore, iNKT cells are considered an attractive target for the treatment of human autoimmune disorders. However, in our opinion several concerns must be addressed before iNKT cell manipulation can be safely used for treating patients with autoimmune diseases. Here, we discuss the therapeutic potential of this approach, and its possible pitfalls.
引用
收藏
页码:471 / 476
页数:6
相关论文
共 57 条
[1]   Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity [J].
Akbari, O ;
Stock, P ;
Meyer, E ;
Kronenberg, M ;
Sidobre, S ;
Nakayama, T ;
Taniguchi, M ;
Grusby, MJ ;
DeKruyff, RH ;
Umetsu, DT .
NATURE MEDICINE, 2003, 9 (05) :582-588
[2]   Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission [J].
Araki, M ;
Kondo, T ;
Gumperz, JE ;
Brenner, MB ;
Miyake, S ;
Yamamura, T .
INTERNATIONAL IMMUNOLOGY, 2003, 15 (02) :279-288
[3]   Association between alpha beta TCR(+)CD4(-)CD8(-) T-cell deficiency and IDDM in NOD/Lt mice [J].
Baxter, AG ;
Kinder, SJ ;
Hammond, KJL ;
Scollay, R ;
Godfrey, DI .
DIABETES, 1997, 46 (04) :572-582
[4]   NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells [J].
Beaudoin, L ;
Laloux, V ;
Novak, J ;
Lucas, B ;
Lehuen, A .
IMMUNITY, 2002, 17 (06) :725-736
[5]   Autoreactivity by design: Innate B and T lymphocytes [J].
Bendelac, A ;
Bonneville, M ;
Kearney, JF .
NATURE REVIEWS IMMUNOLOGY, 2001, 1 (03) :177-186
[6]   CD1: Antigen presentation and T cell function [J].
Brigl, M ;
Brenner, MB .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :817-890
[7]   CD1 expression is differentially regulated by microglia, macrophages and T cells in the central nervous system upon inflammation and demyelination [J].
Busshoff, U ;
Hein, A ;
Iglesias, A ;
Dörries, R ;
Régnier-Vigouroux, A .
JOURNAL OF NEUROIMMUNOLOGY, 2001, 113 (02) :220-230
[8]   Suppression of collagen-induced arthritis by natural killer T cell activation with OCK a sphingosine-truncated analog of α-galactosylceramide [J].
Chiba, A ;
Oki, S ;
Miyamoto, K ;
Hashimoto, H ;
Yamamura, T ;
Miyake, S .
ARTHRITIS AND RHEUMATISM, 2004, 50 (01) :305-313
[9]   Ligation of intestinal epithelial CD1d induces bioactive IL-10: Critical role of the cytoplasmic tail in autocrine signaling [J].
Colgan, SP ;
Hershberg, RM ;
Furuta, GT ;
Blumberg, RS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) :13938-13943
[10]   Activation of invariant NKT cells by αGalCer administration protects mice from MOG35-55-induced EAE:: critical roles for administration route and IFN-γ [J].
Furlan, R ;
Bergami, A ;
Cantarella, D ;
Brambilla, E ;
Taniguchi, M ;
Dellabona, P ;
Casorati, G ;
Martino, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (07) :1830-1838